FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283711773> ?p ?o ?g. }

• W4283711773 endingPage "1330" @default.
• W4283711773 startingPage "1330.1" @default.
• W4283711773 abstract "Background The use of Janus kinase inhibitors (JAKi) is approved for adults with rheumatoid arthritis (RA) with moderate to severe activity. Although there is increasing data about baricitinib and tofacitinib in daily clinical practice, data about adherence and persistence in real-life is scarce. Objectives (i) To evaluate the adherence and persistence of tofacitinib and baricitinib in RA patients in a real-life setting. (ii) To assess the influence of treatment adherence to therapeutic persistence. Methods Retrospective longitudinal observational study that included all patients with RA who were treated with tofacitinib and/or baricitinib between 2017/10 and 2021/05 in a tertiary hospital. Demographic, clinical and pharmacological data were collected from electronic medical and pharmacy claim records. Kaplan-Meier survival analysis and log-rank test were performed to calculate and compare treatment persistence, respectively. Drug adherence was assessed with the Medication Possession Ratio (MPR). The effect of therapeutic adherence on treatment persistence was evaluated with a linear regression model. Results We included 136 cases: 30 treated with tofacitinib [28.6%], 44 with baricitinib [41.9%] and 31 with both [29.5%] corresponding to 105 RA patients. In our sample 86.7% of the patients were women with a mean age (± SD) of 63 (± 13) years. At the start of treatment, patients had a mean disease activity score DAS28-ESR (± SD) of 5.1 (± 1.2) and they had previously received a median (range) of 3 (0-8) biologic agents for RA. During the study period, 40 (29.4%) and 38 (27.9%) patients treated with tofacitinib and baricitinib, respectively, discontinued the treatment. Mean treatment persistence was 363 days (95%CI=2-1.282) in tofacitinib group and 406 days (CI95%=8-1.300) in baricitinib group. There were no statistical differences in treatment survival (HR=1.01 [95CI%=0.59-1.71]; p=0.97). Mean MPR was 91% in both groups. There was no statistically significant correlation between therapeutic adherence and treatment persistence (p=0.21). Conclusion The results showed no significant differences between treatment persistence and adherence of tofacitinib and baricitinib in our patients with rheumatoid arthritis. In our cohort, therapeutic adherence was high and it did not influence treatment persistence. Disclosure of Interests None declared" @default.
• W4283711773 created "2022-06-30" @default.
• W4283711773 creator A5011718531 @default.
• W4283711773 creator A5028752927 @default.
• W4283711773 creator A5038167494 @default.
• W4283711773 creator A5048403572 @default.
• W4283711773 creator A5049133478 @default.
• W4283711773 creator A5049868201 @default.
• W4283711773 creator A5050303227 @default.
• W4283711773 creator A5053126790 @default.
• W4283711773 creator A5069505685 @default.
• W4283711773 creator A5084344121 @default.
• W4283711773 date "2022-05-23" @default.
• W4283711773 modified "2023-10-14" @default.
• W4283711773 title "AB0402 THERAPEUTIC ADHERENCE AND PERSISTENCE OF TOFACITINIB AND BARICITINIB IN RHEUMATOID ARTHRITIS PATIENTS IN DAILY CLINICAL PRACTICE." @default.
• W4283711773 doi "https://doi.org/10.1136/annrheumdis-2022-eular.2116" @default.
• W4283711773 hasPublicationYear "2022" @default.
• W4283711773 type Work @default.
• W4283711773 citedByCount "1" @default.
• W4283711773 countsByYear W42837117732023 @default.
• W4283711773 crossrefType "journal-article" @default.
• W4283711773 hasAuthorship W4283711773A5011718531 @default.
• W4283711773 hasAuthorship W4283711773A5028752927 @default.
• W4283711773 hasAuthorship W4283711773A5038167494 @default.
• W4283711773 hasAuthorship W4283711773A5048403572 @default.
• W4283711773 hasAuthorship W4283711773A5049133478 @default.
• W4283711773 hasAuthorship W4283711773A5049868201 @default.
• W4283711773 hasAuthorship W4283711773A5050303227 @default.
• W4283711773 hasAuthorship W4283711773A5053126790 @default.
• W4283711773 hasAuthorship W4283711773A5069505685 @default.
• W4283711773 hasAuthorship W4283711773A5084344121 @default.
• W4283711773 hasBestOaLocation W42837117731 @default.
• W4283711773 hasConcept C105795698 @default.
• W4283711773 hasConcept C126322002 @default.
• W4283711773 hasConcept C167135981 @default.
• W4283711773 hasConcept C1862650 @default.
• W4283711773 hasConcept C195910791 @default.
• W4283711773 hasConcept C27403532 @default.
• W4283711773 hasConcept C2776233030 @default.
• W4283711773 hasConcept C2777178219 @default.
• W4283711773 hasConcept C2777575956 @default.
• W4283711773 hasConcept C2778886723 @default.
• W4283711773 hasConcept C33923547 @default.
• W4283711773 hasConcept C53084192 @default.
• W4283711773 hasConcept C71924100 @default.
• W4283711773 hasConcept C72563966 @default.
• W4283711773 hasConceptScore W4283711773C105795698 @default.
• W4283711773 hasConceptScore W4283711773C126322002 @default.
• W4283711773 hasConceptScore W4283711773C167135981 @default.
• W4283711773 hasConceptScore W4283711773C1862650 @default.
• W4283711773 hasConceptScore W4283711773C195910791 @default.
• W4283711773 hasConceptScore W4283711773C27403532 @default.
• W4283711773 hasConceptScore W4283711773C2776233030 @default.
• W4283711773 hasConceptScore W4283711773C2777178219 @default.
• W4283711773 hasConceptScore W4283711773C2777575956 @default.
• W4283711773 hasConceptScore W4283711773C2778886723 @default.
• W4283711773 hasConceptScore W4283711773C33923547 @default.
• W4283711773 hasConceptScore W4283711773C53084192 @default.
• W4283711773 hasConceptScore W4283711773C71924100 @default.
• W4283711773 hasConceptScore W4283711773C72563966 @default.
• W4283711773 hasIssue "Suppl 1" @default.
• W4283711773 hasLocation W42837117731 @default.
• W4283711773 hasOpenAccess W4283711773 @default.
• W4283711773 hasPrimaryLocation W42837117731 @default.
• W4283711773 hasRelatedWork W2014330392 @default.
• W4283711773 hasRelatedWork W2052064556 @default.
• W4283711773 hasRelatedWork W2132809463 @default.
• W4283711773 hasRelatedWork W2755978387 @default.
• W4283711773 hasRelatedWork W2916556513 @default.
• W4283711773 hasRelatedWork W2939528202 @default.
• W4283711773 hasRelatedWork W2972486011 @default.
• W4283711773 hasRelatedWork W3085086630 @default.
• W4283711773 hasRelatedWork W4226373090 @default.
• W4283711773 hasRelatedWork W4283653027 @default.
• W4283711773 hasVolume "81" @default.
• W4283711773 isParatext "false" @default.
• W4283711773 isRetracted "false" @default.
• W4283711773 workType "article" @default.